Cochrane Scientific Committee Meeting

Chairs: Ana Marušić and Philippe Ravaud
Organiser: Ella Flemyng

31 March 2019
Krakow, Poland

Trusted evidence.
Informed decisions.
Better health.
Welcome and overview

01 First session is on general business and includes updates from Cochrane

02 Second session concentrates on the Cochrane Scientific Committee set-up

03 Third session covers new methods discussions and the process

04 Fourth session reflects on previously discussed and approved methods
General business and updates

First session (09:00-10:30)

Chaired by Ana Marušić
Approval of minutes

Approval of the previous meeting’s minutes – see Paper 1.
Content Strategy methods projects

Presented by Ella Flemyng
Overview of Methods Implementation Projects in the Content Strategy

Full details on the different projects are in **Paper 2:**

- Risk of Bias 2 (RoB 2).
- Living systematic reviews.
- Network meta-analysis (NMA)
- Rapid reviews.
- Prognosis reviews.
- Clinical Study Reports as the main data source for drug intervention reviews.
Risk of Bias 2 (RoB 2)

- 2019 is the year for technology and process piloting.
- Development of training, guidance and support.
- Dependencies on different process and platforms.
- Authors can begin using RoB 2 but we are not mandating.
- Roll-out requires consultation with multiple stakeholders and likely to be staggered across/within Networks in 2020.
Living systematic reviews

- Evaluation of the pilot has been finalised.
- Development of training, guidance and support.
- Aim to have identified and initiated living systematic reviews across all Networks by the end of 2019.
Network meta-analysis (NMA)

• New CIL module and chapter in the Cochrane Handbook.
• Further development of training and guidance.
• Capacity building of NMA expertise to support CRGs as authors, peer reviewers and advisors.
• Development of consensus-based methodological standards.
• Technological developments will involve tools for conducting NMA, RevMan and data structure projects.
• Aim to have NMAs in four Networks by the end of 2019.
Rapid reviews

- Identified existing definitions and abbreviated methods for rapid reviews, initiated two projects to fill knowledge gaps.
- Develop a consensus-based definition of rapid reviews.
- Complete a detailed SWOT and develop a business case for Cochrane to consider implementation rapid reviews.
- Aim to put together a proposal for the Governing Board to consider at Colloquium 2019.
Prognosis reviews

• Templates and guidance developed.
• Network of prognosis review experts support CRGs as authors, peer reviewers and advisors.
• Technological developments will involve RevMan and data structure projects.
• Further development of training and guidance.
• 21 prognosis reviews initiated and aim to publish at least six by the end of 2019.
Clinical Study Reports

• International consultation meeting on 16 May 2019 (London, UK).

• Will discuss the feasibility of using Clinical Study Reports as the main source of data in Cochrane drug intervention reviews.

• If deemed feasible, an implementation plan will be developed and a pilot initiated with three Reviews.
Cochrane Handbook for Systematic Reviews of Interventions

Presented by Ella Flemyng
Cochrane Handbook

- Tentative publication in Quarter 3 2019.
- PDF chapters available for Cochrane members.
- Discussing options for the publicly available, online version.
- Finalising an implementation plan to involve all key stakeholders, inc. CRGs and Networks.
Cochrane’s data sharing policy

Presented by David Tovey
Cochrane’s data sharing policy

See Paper 3.
Scientific Committee set-up

Second session (11:00-12:30)

Chaired by Philippe Ravaud
Methods approval process

Discussion to clarify the process, including what roles and responsibilities the Scientific Committee (SC) and Methods Executive have in the process.

Proposal for discussion:

- New submissions initially assessed by Methods Executive, who decide:
  - Escalation to SC for a decision (see criteria in Paper 4)
  - Further revisions/developments required before a decision.
  - Integration into, or establish new, methods (implementation) projects.
  - Not taken forward.

- Potential benefits and implications:
  - SC only consider submissions within their remit.
  - Could encourage ECRs/MCRs to submit for smaller project consideration (potential for mentor set-up?).
  - Additional workload for Methods Executive.
Cochrane’s method community roles

Discussion to finalise the roles and responsibilities document, which will include the Scientific Committee, Methods Executive, Methods Groups, Methods Support Unit, Methods Implementation Coordinator and other CET roles.

See Paper 4.
2019/2020 strategic priorities

Discuss and consider strategic objectives and priorities for the Scientific Committee.
New methods discussions

Third session (13:30-15:00)
Chaired by Ana Marušić
New methods submissions

See Appendix 1.

**Title:** Use of interactive analysis framework to facilitate diagnostic test accuracy and network meta-analyses analyses

**Submitted by:** Alex Sutton, University of Leicester, UK

**Aim(s):** To develop interactive software to facilitate meta-analysis which otherwise requires specialist software routines which are difficult to use by non-statistical experts. Also, to provide a powerful interface so even statisticians will want to use the software for its power, speed, flexibility and ease of use.
Process for new submissions

Discuss the general process for submissions and how the Scientific Committee could proactively encourage or request methods submissions from Methods Groups.

Methods or tools for future consideration include:

- Risk of Bias due to Missing Evidence (RoBME).
- Tool for Addressing Conflict of Interests in Trials (TACIT).
- Semi automation methods.
- Prognosis methods.
- Standalone qualitative evidence synthesis (following PHHSN two-year pilot).
Reflection on previously approved methods

Fourth session (15:30-17:00)

Chaired by Philippe Ravaud
Reflections on past decisions

Discuss progress of methods following decisions.

See Appendix 2.

- RoB 2
- ROBINS-I
- Cumulative meta-analysis
- Inclusion of results from searching study registries
- Meta analysis of prevalence and risk
- Meta-regression

- Frameworks for Adaptive Meta-analysis (FAME)
- Time-to-event outcomes for clinical conclusions.
- Data-based predictive distribution for between-study heterogeneity
- CSR inclusion
- Sequential methods to adjust P values in repeated meta-analysis
Next Scientific Committee meetings

2019 teleconferences?
Cochrane Colloquium 2019?
Any other business?
Thank you!

Chairs: Ana Marušić and Philippe Ravaud
Organiser: Ella Flemyng

31 March 2019
Krakow, Poland